Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine

R. Casolino, C. Braconi, G. Malleo, S. Paiella, C. Bassi, M. Milella, S. B. Dreyer, F. E.M. Froeling, D. K. Chang, A. V. Biankin*, T. Golan

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

This review summarises the recent evidence on preoperative therapeutic strategies in pancreatic cancer and discusses the rationale for an imminent need for a personalised therapeutic approach in non-metastatic disease. The molecular diversity of pancreatic cancer and its influence on prognosis and treatment response, combined with the failure of ‘all-comer’ treatments to significantly impact on patient outcomes, requires a paradigm shift towards a genomic-driven approach. This is particularly important in the preoperative, potentially curable setting, where a personalised treatment allocation has the substantial potential to reduce pancreatic cancer mortality.

Original languageEnglish
Pages (from-to)183-196
Number of pages14
JournalAnnals of Oncology
Volume32
Issue number2
DOIs
StatePublished - Feb 2021
Externally publishedYes

Keywords

  • Pancreatic cancer
  • neoadjuvant
  • precision medicine
  • predictive biomarkers
  • preoperative
  • prognostic biomarkers

Fingerprint

Dive into the research topics of 'Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine'. Together they form a unique fingerprint.

Cite this